Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

101. Compound kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 37 RCTs following the PRISMA guidelines

Compound kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 37 RCTs following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

102. Comparison of anlotinib and erlotinib in refractory non-small cell lung cancer: a systematic review and meta-analysis of safety and efficacy

Comparison of anlotinib and erlotinib in refractory non-small cell lung cancer: a systematic review and meta-analysis of safety and efficacy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

103. Comparison of end-of-life care in people with COPD or lung cancer: a systematic review

Comparison of end-of-life care in people with COPD or lung cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

104. Histone deacetylase (HDAC) inhibitors for non-small cell lung cancer: a patient-level meta-analysis

Histone deacetylase (HDAC) inhibitors for non-small cell lung cancer: a patient-level meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

105. Long-term survival of surgically treated synchronous multiple primary lung cancer

Long-term survival of surgically treated synchronous multiple primary lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

106. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis following the PRISMA guidelines

Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

107. Meta-analysis of pulmonary resection for metastatic colorectal cancer to the lung

Meta-analysis of pulmonary resection for metastatic colorectal cancer to the lung Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

108. A comparison of prognosis of part-solid and pure-solid tumors in lung cancer: a systematic review and meta-analysis

A comparison of prognosis of part-solid and pure-solid tumors in lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

109. Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines

Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

110. Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis

Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

111. Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer

Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

112. A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer.

A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

113. The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis

The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

114. The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis

The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

115. A systematic review of Mendelian randomization studies in lung cancer

A systematic review of Mendelian randomization studies in lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

116. A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer

A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

117. A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II

A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

118. Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis

Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

119. Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review

Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

120. A systematic review on oncometabolomics in lung cancers

A systematic review on oncometabolomics in lung cancers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO